Cargando…

Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer

Circulating tumor DNA (ctDNA) has contributed immensely to the management of hematologic malignancy and is now considered a valuable detection tool for solid tumors. ctDNA can reflect the real-time tumor burden and be utilized for analyzing specific cancer mutations via liquid biopsy which is a non-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Xiaoxu, Yu, Shaokun, Jiang, Yingying, Xiang, Yan, Lu, Kaihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646858/ https://www.ncbi.nlm.nih.gov/pubmed/36387176 http://dx.doi.org/10.3389/fonc.2022.1027664

Ejemplares similares

Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
por: Peng, Yan, et al.
Publicado: (2021)

Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study
por: Fang, Xiaoxu, et al.
Publicado: (2023)

SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?
por: Turcas, Cristina, et al.
Publicado: (2020)

Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML
por: Georgi, Julia-Annabell, et al.
Publicado: (2022)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer
por: Hanssen, Annkathrin, et al.
Publicado: (2015)

Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review
por: Zhu, Lemei, et al.
Publicado: (2023)

Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer
por: Peng, Muyun, et al.
Publicado: (2020)

Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study
por: Dong, Daling, et al.
Publicado: (2023)

Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer
por: Yang, Jialiang, et al.
Publicado: (2021)

The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice
por: Turner, Rose, et al.
Publicado: (2022)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer
por: Xiang, Yan, et al.
Publicado: (2022)

Corrigendum: Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study
por: Dong, Daling, et al.
Publicado: (2023)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
por: Bernardi, Massimo, et al.
Publicado: (2022)

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?
por: Guolo, Fabio, et al.
Publicado: (2022)

MRD Tailored Therapy in AML: What We Have Learned So Far
por: Ngai, Lok Lam, et al.
Publicado: (2021)

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update
por: Kapeleris, Joanna, et al.
Publicado: (2022)

The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer
por: Cai, Jun, et al.
Publicado: (2022)

An Improved Detection of Circulating Tumor DNA in Extracellular Vesicles-Depleted Plasma
por: Sun, Li, et al.
Publicado: (2021)

Adjunctive Use of Circulating Tumor DNA Testing in Detecting Pancreas Cancer Recurrence
por: Soyano, Aixa E., et al.
Publicado: (2019)

Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
por: Chakrabarti, Sakti, et al.
Publicado: (2022)

Circulating Tumor DNA Analyses as a Potential Marker of Recurrence and Effectiveness of Adjuvant Chemotherapy for Resected Non-Small-Cell Lung Cancer
por: Kuang, Peng-Peng, et al.
Publicado: (2021)

Circulating Tumor Cell and Metabolites as Novel Biomarkers for Early-Stage Lung Cancer Diagnosis
por: Wan, Lingling, et al.
Publicado: (2021)

Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful?
por: Cengiz Seval, Guldane, et al.
Publicado: (2022)

Patient specific real-time PCR in precision medicine – Validation of IG/TR based MRD assessment in lymphoid leukemia
por: Schilhabel, Anke, et al.
Publicado: (2023)

Precision Oncology: Artificial Intelligence and DNA Methylation Analysis of Circulating Cell-Free DNA for Lung Cancer Detection
por: Bahado-Singh, Ray, et al.
Publicado: (2022)

Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal Cancer
por: Knebel, Franciele H., et al.
Publicado: (2019)

Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer
por: Faugeroux, Vincent, et al.
Publicado: (2014)

Five Technologies for Detecting the EGFR T790M Mutation in the Circulating Cell-Free DNA of Patients With Non-small Cell Lung Cancer: A Comparison
por: Chen, Yi-Lin, et al.
Publicado: (2019)

Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer
por: Jiang, Jiahong, et al.
Publicado: (2020)

Case Report: Vemurafenib Treatment in Brain Metastases of BRAF(S365L)-Mutant Lung Papillary Cancer by Genetic Sequencing of Cerebrospinal Fluid Circulating Tumor DNA Detection
por: Jiang, Jianing, et al.
Publicado: (2021)

The Potential Clinical Utility of Circulating Tumor DNA in Esophageal Adenocarcinoma: From Early Detection to Therapy
por: Kosovec, Juliann E., et al.
Publicado: (2018)

Detection of Circulating Tumor Cell Molecular Subtype in Pulmonary Vein Predicting Prognosis of Stage I–III Non-small Cell Lung Cancer Patients
por: Dong, Jingsi, et al.
Publicado: (2019)

Aneuploid subtypes of circulating tumor cells and circulating tumor-derived endothelial cells predict the overall survival of advanced lung cancer
por: Zhang, Jie, et al.
Publicado: (2023)

The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Wang, Haowei, et al.
Publicado: (2021)

Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer
por: Knapp, Brendan, et al.
Publicado: (2022)

Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT
por: Sun, Qian, et al.
Publicado: (2022)

Liquid Biopsy-Based Biosensors for MRD Detection and Treatment Monitoring in Non-Small Cell Lung Cancer (NSCLC)
por: Sardarabadi, Parvaneh, et al.
Publicado: (2021)

The Challenges of Detecting Circulating Tumor Cells in Sarcoma
por: Tellez-Gabriel, Marta, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fnbh05m52eg04an4ksm0hkgu0o